MDXG Stock Analysis: Buy, Sell, or Hold?
MDXG - MiMedx Group, Inc
$3.95
0.05 (1.28%)
▲
5d:
+3.67%
30d:
+10.64%
90d:
+0.0%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Jul 29, 2026
25d
Get Alerted When MDXG Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: MDXG shows positive signals but monitor for confirmation. Market pricing in 0.6% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: MDXG shows positive signals but monitor for confirmation. Market pricing in 0.6% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: MDXG is currently trading at $3.95, which is considered extended relative to its 30-day fair value range of $3.60 to $3.77. The stock's valuation (Forward PE: 27.6) is in line with its historical norms (27.1). At these levels, the market is pricing in 0.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, MDXG is in a strong downtrend. The price is approaching resistance at $4.03. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: MDXG has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.60 (+67.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MDXG is in a strong downtrend. The price is approaching resistance at $4.03. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: MDXG has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.60 (+67.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.60 -
$3.77
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
62.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 67.1% below Wall St target ($6.60)
- NEUTRAL: Market pricing in 0.6% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$3.60 -
$3.77
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.63
Resistance Level
$4.03
Current Trend
Strong Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
27.56
Wall Street Target
$6.60
(+67.1%)
Revenue Growth (YoY)
-33.1%
Earnings Growth (YoY)
99.5%
Profit Margin
7.9%
Valuation Premium vs History
+0.6% premium
PE vs Historical
27.6 vs 27.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.6%
(market-implied from PE analysis)
1-Year Target
$3.97
(+1%)
2-Year Target
$4.00
(+1%)
3-Year Target
$4.02
(+2%)
3-Yr Target (if PE normalizes)
(PE: 28→27)
PE COMPRESSION
$3.95
(+0%)
Earnings growth offset by PE compression
📈
Valuation based on Current Earnings
Trailing PE: 19.50 | Current EPS (TTM): $0.20
Bull Case
$3.07
(-22%)
Analyst growth -28.3%, PE expands to 21.5
Base Case
$2.79
(-29%)
Market implied -28.3%, PE stable at 19.5
Bear Case
$2.65
(-33%)
Severe decline -20.0%, PE contracts to 16.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 02, 2026 9:42 PM ET
Data refreshes hourly during market hours. Next update: 10:42 PM
Data refreshes hourly during market hours. Next update: 10:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MDXG showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 55 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 63 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 63 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
